PET scans for advanced breast cancer treatment planning
Part of Cancer clinical trials.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have advanced breast cancer that has spread or cannot be removed with surgery
- You are about to start a new treatment (hormone therapy, targeted therapy, chemo, immunotherapy, or a mix)
- You are willing to have repeat PET scans and CT scans over 48 weeks
- You have not had any previous treatment for advanced breast cancer
- You are generally well enough to be out of bed (ECOG 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial studies how an FDG PET/CT scan (a special imaging test that looks for active cancer activity) can be used in people with high-risk primary or recurring breast cancer. It may help doctors better identify areas of concern and guide future care.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
This trial compares two types of scans (PET/CT and CT) to see which is better at monitoring metastatic breast cancer. If you are starting your first treatment for breast cancer that has spread to other parts of the body, this study may help determine the best way to track your disease.
Hear when a new Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.